Blueprint Medicines Corporation BPMC
129.46 0.00 (+0.00%)
At closeJul 18, 2025, 4:00 PM EDT
129.46 Day range 129.46
52-week range unavailable
- YTD
- +48.43%
- 1 year
- +13.20%
Analyst view
Consensus: hold
Hold
Price target (mean) 130.29 +0.6% upside
Now 129.46
- Target (low)
- 129.00
- Target (mean)
- 130.29
- Target (high)
- 135.00
Ratings (0m) 1 0 buy · 1 hold · 0 sell
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 1
- 1 month ago 19
- 2 months ago 21
- 3 months ago 21
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.38 | -0.38 – -0.38 | -0.80 | +52.5% | 174.80M | +26.5% | 1 |
| Next quarter | -0.11 | -0.11 – -0.11 | -0.89 | +87.6% | 195.00M | +52.1% | 1 |
| Current year | -0.71165 | -2.84 – 2.92 | -3.83 | +81.4% | 723.30M | +42.2% | 7 |
| Next year | 1.15 | 1.15 – 1.15 | -0.71165 | +261.6% | 1.02B | +40.3% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 17, 2025 | Wells Fargo | Downgrade | Overweight | Equal-Weight |
| Jun 5, 2025 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Jun 5, 2025 | UBS | Maintained | Neutral | Neutral |
| Jun 4, 2025 | Citigroup | Upgrade | Sell | Neutral |
| Jun 3, 2025 | JMP Securities | Downgrade | Market Outperform | Market Perform |
| Jun 3, 2025 | Wolfe Research | Downgrade | Outperform | Peer Perform |
| Jun 2, 2025 | Scotiabank | Downgrade | Sector Outperform | Sector Perform |
| Jun 2, 2025 | JP Morgan | Downgrade | Overweight | Neutral |
| Jun 2, 2025 | Wedbush | Downgrade | Outperform | Neutral |
| Jun 2, 2025 | Needham | Downgrade | Buy | Hold |
| May 2, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Apr 28, 2025 | Needham | Maintained | Buy | Buy |
| Apr 16, 2025 | Wedbush | Reiterated | Outperform | Outperform |
| Apr 8, 2025 | Needham | Reiterated | Buy | Buy |
| Mar 17, 2025 | Jefferies | Initiated | — | Buy |
| Mar 7, 2025 | Scotiabank | Initiated | — | Sector Outperform |
| Mar 3, 2025 | Citizens Capital Markets | Reiterated | Market Outperform | Market Outperform |
| Feb 14, 2025 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| Feb 14, 2025 | Needham | Reiterated | Buy | Buy |
| Feb 14, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Feb 13, 2025 | Needham | Reiterated | Buy | Buy |
| Feb 4, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Jan 27, 2025 | Piper Sandler | Maintained | Neutral | Neutral |
| Jan 15, 2025 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| Jan 13, 2025 | Wedbush | Reiterated | Outperform | Outperform |
| Jan 13, 2025 | Needham | Reiterated | Buy | Buy |
| Jan 2, 2025 | Stephens & Co. | Reiterated | Overweight | Overweight |
| Dec 17, 2024 | Needham | Reiterated | Buy | Buy |
| Dec 11, 2024 | Guggenheim | Reiterated | Buy | Buy |
| Dec 9, 2024 | JMP Securities | Reiterated | Market Outperform | Market Outperform |